BofA Securities Upgrades Akero Therapeutics (AKRO) to Buy

BofA Securities analyst Jason Zemansky upgraded Akero Therapeutics (NASDAQ: AKRO) from Neutral to Buy with a price target of $63.00 (from $35.00).

For an analyst ratings summary and ratings history on Akero Therapeutics click here. For more ratings news on Akero Therapeutics click here.

Shares of Akero Therapeutics closed at $54.00 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
• Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins